SCHEMBL6921699

SCHEMBL6921699

S=CNc1ccc(Cc2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.50
IDH1 O75874 1/20 0.44
CYP2C9 P11712 1/20 0.42
LTA4H P09960 2/20 0.41
LSS P48449 1/20 0.41
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
CA14 Q9ULX7 1/20 0.39
PLA2G10 O15496 1/20 0.38
PLA2G2A P14555 1/20 0.38
LMNA P02545 1/20 0.38
HNF4A P41235 1/20 0.38
MPO P05164 1/20 0.38
BCL2 P10415 1/20 0.38
BCL2L1 Q07817 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8763190 0.91 ALDH1A1 (0.40) CALM1CA1CA2LMNAALDH1A1
SCHEMBL57469 0.79
SCHEMBL14855299 0.79 ALDH1A1 (0.64) CALM1IDH1CYP2C9LTA4HCA12
SCHEMBL8764231 0.76 ALDH1A1 (0.35) ALDH1A1
SCHEMBL14342427 0.76 MEN1 (0.59) LTA4HLMNAALDH1A1
SCHEMBL7361947 0.76 ALDH1A1 (0.62) CYP2C9LMNAALDH1A1
SCHEMBL1269897 0.76 ALDH1A1 (0.43) CA12CA1CA2CA9CA14
SCHEMBL284700 0.75 CALM1 (0.63) CALM1IDH1CYP2C9LTA4HSLC1A3
SCHEMBL10467228 0.74 HPGD (0.42) CYP2C9CA2ALDH1A1
SCHEMBL972712 0.74 CALM1 (0.92) CALM1IDH1CYP2C9LTA4HCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515002-B2 4-(4-(1-phenyl-5-propylpyrazol4-yl)(1,3-thiazol-2-yl))-5 -methylthiothiophene-2-carboxamidine, for example; complement inhibitors; treating tissue damage, inflammation, or autoimmune diseases 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-02-04 US disclosed
EP-1152759-A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-11-14 EP disclosed
US-6291514-B1 Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-09-18 US disclosed
WO-2000047194-A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO disclosed